{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:19:35Z","timestamp":1758050375778,"version":"3.44.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"Leo Pharma AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2022.10.008","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:46:10Z","timestamp":1670373970000},"page":"212-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pr\u00e9vention et prise en charge des thromboses associ\u00e9es au cancer: questions pratiques \u00e0 propos de l\u2019anticoagulation"],"prefix":"10.1016","volume":"110","author":[{"given":"David","family":"Malka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Smadja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lesur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.10.008_bib0315","doi-asserted-by":"crossref","first-page":"e000188","DOI":"10.1136\/esmoopen-2017-000188","article-title":"Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer\u00a0: review of the literature on current practice and emerging options","volume":"2","author":"Ay","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0320","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0325","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12102","article-title":"Managing thrombosis in cancer patients","volume":"2","author":"Wang","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0330","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/cancers11010071","article-title":"Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges","volume":"11","author":"Frere","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0340","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0345","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","article-title":"BACAP Consortium, incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes","volume":"158","author":"Frere","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1684\/hma.2010.0412","article-title":"Angiogen\u00e8se, traitement h\u00e9parinique et pathologies canc\u00e9reuses","volume":"16","author":"Smadja","year":"2010","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0355","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.critrevonc.2007.01.001","article-title":"Cancer-associated thrombosis","volume":"62","author":"Zwicker","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0360","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, thrombo-inflammation, and cancer: collaborating with the enemy","volume":"10","author":"Palacios-Acedo","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0365","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0370","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"International Initiative on Thrombosis and Cancer (ITAC) advisory panel, 2022\u00a0international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0375","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0380","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021\u00a0guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0385","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.rmr.2021.03.001","article-title":"pour le groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE, Traitement de la maladie veineuse thromboembolique au cours du cancer. Mise \u00e0 jour mars 2021","volume":"38","author":"Mah\u00e9","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0390","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJMe2004220","article-title":"Anticoagulant Therapy for Venous Thromboembolism in Cancer","volume":"382","author":"Lee","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0395","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bulcan.2021.11.015","article-title":"Traitement de la maladie veineuse thromboembolique au cours du cancerTreatment of cancer associated thrombosis","volume":"109","author":"Hindr\u00e9","year":"2022","journal-title":"Bull Cancer"},{"year":"2021","series-title":"Prise en charge de la maladie thromboembolique veineuse en canc\u00e9rologie","author":"AFSOS","key":"10.1016\/j.bulcan.2022.10.008_bib0400"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.06.015","article-title":"Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences","volume":"129","author":"Bellesoeur","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0410","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bulcan.2020.02.010","article-title":"Place des anticoagulants oraux directs dans la prise en charge de la maladie thromboembolique veineuse associ\u00e9e au cancer en 2020","volume":"107","author":"Auditeau","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0415","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jth.13942","article-title":"Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis","volume":"16","author":"Chan","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0420","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0425","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"CAT-prediction collaborators, The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0430","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0435","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1111\/jth.15503","article-title":"Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer","volume":"19","author":"Guman","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0440","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"COMPASS\u2013CAT Working group. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0445","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-018-1120-9","article-title":"Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients","volume":"35","author":"Rupa-Matysek","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0450","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","article-title":"External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: The COMPASS-CAT venous thromboembolism risk assessment model","volume":"25","author":"Spyropoulos","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0455","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0460","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","article-title":"Thrombotic risk from chemotherapy and other cancer therapies","volume":"179","author":"Jiang","year":"2019","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0465","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0470","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10549-018-05086-8","article-title":"Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors","volume":"174","author":"Xu","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0475","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/cancers12092493","article-title":"Gemcitabine and platinum-based agents for the prediction of cancer-associated venous thromboembolism: results from the vienna cancer and thrombosis study","volume":"12","author":"Moik","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0480","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.3390\/cancers13184603","article-title":"Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale?. A systematic review and meta-analysis","volume":"13","author":"Saerens","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0485","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0490","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0495","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2022.10.008_bib0500","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-022-02649-x","article-title":"Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors","volume":"54","author":"Alma","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0505","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.3390\/cancers13184606","article-title":"Thrombotic complications associated with immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0510","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/bmjspcare-2019-002106","article-title":"Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment","volume":"11","author":"Marin","year":"2021","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0515","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000\u00a0patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0520","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0525","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1016\/S2352-3026(20)30293-3","article-title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","volume":"7","author":"Sch\u00fcnemann","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0530","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021\u00a0European Heart Rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0535","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0540","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"CASSINI Investigators, rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0545","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/cancers12020367","article-title":"Primary thromboprophylaxis in ambulatory cancer patients: where do we stand?","volume":"12","author":"Mulder","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0550","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"Carrier","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0555","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.bulcan.2022.10.008_bib0560","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0565","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0570","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0575","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0580","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0585","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0590","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620936325","article-title":"Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms","volume":"26","author":"Peixoto de Miranda \u00c9JF","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0595","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620979592","article-title":"Tinzaparin safety in patients with cancer and renal impairment: a systematic review","volume":"27","author":"Vathiotis","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0600","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/2042098617719815","article-title":"Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients","volume":"8","author":"Forbes","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0605","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers11010048","article-title":"Treatment and prevention of cancer-associated thrombosis in frail patients: tailored management","volume":"11","author":"Scott\u00e9","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0610","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0615","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bulcan.2022.10.008_bib0310","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/apt.13281","article-title":"Systematic review: colitis associated with anti-CTLA-4\u00a0therapy","volume":"42","author":"Gupta","year":"2015","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122004246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122004246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:23Z","timestamp":1757792243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122004246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122004246"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9vention et prise en charge des thromboses associ\u00e9es au cancer: questions pratiques \u00e0 propos de l\u2019anticoagulation","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}